Document is current
Any future updates will be listed below
-
Authors
Babl, Nathalie https://orcid.org/0000-0002-5584-322X
Decking, Sonja-Maria
Voll, Florian
Althammer, Michael
Sala-Hojman, Ada
Ferretti, Roberta
Korf, Clarissa
Schmidl, Christian
Schmidleithner, Lisa
Nerb, Benedikt
Matos, Carina
Koehl, Gudrun E
Siska, Peter https://orcid.org/0000-0002-1521-6213
Bruss, Christina
Kellermeier, Fabian
Dettmer, Katja
Oefner, Peter J
Wichland, Marvin
Ugele, Ines
Bohr, Christopher
Herr, Wolfgang
Ramaswamy, Shivapriya
Heinrich, Timo
Herhaus, Christian
Kreutz, Marina
Renner, Kathrin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01791595 at ClinicalTrials.govDocuments that mention this clinical trial
MCT4 blockade increases the efficacy of immune checkpoint blockade
https://doi.org/10.1136/jitc-2023-007349
Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies
https://doi.org/10.1136/jitc-2022-006287
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
-
Funding
Funding for this research was provided by:
Merck KGaA, Darmstadt, Germany (ID: 10.13039/100009945)
Leibniz Institute for Immunotherapy Regensburg (N.A.)
Else Kröner-Fresenius-Foundation (N.A.)
- License Information
